×
Sign in
Menu
Home
Resources
Back To Top
×
Contact the Presenter
×
Add To Cart
×
Test
ELCC 2022 Onsite and Online Congress
Final Programme PDF
Advanced Search
30.03.2022
31.03.2022
01.04.2022
02.04.2022
03.04.2022
Controversy session
ESMO Colloquium
Educational session
Industry Satellite Symposium
Mini Oral session
Multidisciplinary Tumour Board
Multidisciplinary interactive session
Proffered Paper session
Special symposium
11:00
12:00
13:00
14:00
15:00
16:00
17:00
18:00
19:00
20:00
Club A
11:45(1h 30m)
How to use real-world evidence for clinical decision making
15:15(1h 30m)
Perioperative strategies: ICI, TKIs, adjuvant, neoadjuvant
17:00(1h)
Sublobar resection versus lobectomy
Congress Hall
11:45(1h 30m)
ESMO Colloquium supported by Eli Lilly and Co. - One tumour, many faces: Optimising testing, targeting and monitoring oncogene-addicted NSCLC beyond EGFR
15:15(1h 20m)
Proffered Paper session
17:00(1h)
Salvage surgery and RT
Forum Hall
15:15(1h 30m)
First line in non-oncogene addicted
13:30(1h 30m)
Janssen Pharmaceutica - Evolving treatment options and practices in EGFR-mutant NSCLC
17:00(1h)
New TNM classification: Anatomical vs biological
18:15(1h 30m)
Novartis - Management of patients with oncogene-driven NSCLC: The shift towards personalized medicine
11:45(1h)
Surgery vs radiation therapy for stage III NSCLC in the context of immunotherapy
South Hall 2
13:30(1h 30m)
AstraZeneca - CNS disease management in EGFRm NSCLC
17:00(1h)
Mini Oral session 1
15:15(1h 30m)
Minimal residual disease, biological disease
11:45(1h 30m)
More targets, more drugs, more choices, more conflicts
18:15(1h 30m)
Thermo Fisher Scientific - Enabling future improvements in cancer care with fast next -generation sequencing (NGS) results
×
Dialog
×
Sponsored Access
Access to the resources are offered to you by
ESMO Events